Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-04-06. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerpatientsand neckhead andbowel
  Phrases that lowered it: allergicadultadultspainmedication
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Drug's FAERS reports with a death: 8.5% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 88 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 62.3% (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 183920 (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 7.8% (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Primary purpose: supportive care (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 31613 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 257 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer NCT03269344 · started 2017 · scored riskier than 64% of active trials completed
• Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy NCT02480114 · started 2015 · scored riskier than 88% of active trials completed
• Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain NCT02240199 · started 2014 · scored riskier than 44% of active trials completed
• Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery NCT04176419 · started 2020 · scored riskier than 95% of active trials terminated
• Stanford Accelerated Recovery Trial (START) NCT01067144 · started 2010 · scored riskier than 83% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.